Meso

British-Swedish drugmaker AstraZeneca has obtained orphan drug designation from the US Food and Drug Administration (FDA) for its anti-CTLA-4 monoclonal antibody, tremelimumab to treat malignant mesothelioma.

Mesothelioma is a rare and aggressive cancer that affects the lining of the lungs and abdomen, and limited treatments are available for this cancer.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Tremelimuma is a fully human monoclonal antibody that stimulates the immune system to destroy cancer cells through binding to the protein CTLA-4, expressed on the surface of activated T-lymphocytes.

“There is a significant need for new treatment options for patients with mesothelioma because fewer than 5% of patients currently survive beyond five years.”

AstraZeneca global medicines development and immuno-oncology head and senior vice-president Robert Iannone said: “There is a significant need for new treatment options for patients with mesothelioma because fewer than 5% of patients currently survive beyond five years, even when they receive timely diagnosis and care.

“Our aim is to rapidly advance the development of tremelimumab as a potential new treatment option for these patients.”

Along with its biologics research and development arm MedImmune, AstraZeneca has developed tremelimumab. It is part of the broad pipeline of immuno-oncology assets being developed by both firms to harness the body’s own immune system to fight cancer.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Tremelimumab is currently being studied in combination with AstraZeneca’s anti PD-L1 investigational immunotherapy MEDI4736 in tumour types, including non-small cell lung cancer and head and neck cancer.

In addition, it is being studied in combination with Iressa (gefitinib) in EGFR mutated non-small cell lung cancer and with MEDI6469 (a murine OX40 agonist) in solid tumours.

Image: Micrographs showing mesothelioma in a core biopsy. Photo: courtesy of Robertolyra.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
NorthWest EHealth has won three 2025 Pharmaceutical Technology Excellence Awards for Innovation, Safety and Diversity. Explore how its ConneXon platform is transforming SAE reporting and real-time safety oversight, while FARSITE delivers socio-economically inclusive recruitment to boost trial efficiency, data integrity and regulatory-grade representativeness.

Discover the Impact